<DOC>
	<DOCNO>NCT02294396</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy add-on therapy anticholinergic patient overactive bladder ( OAB ) mirabegron .</brief_summary>
	<brief_title>Post-marketing Study Evaluate add-on Therapy With Anticholinergics Patients With Overactive Bladder ( OAB ) Mirabegron .</brief_title>
	<detailed_description>This multicenter , open label study evaluate safety efficacy add-on therapy anticholinergic OAB patient mirabegron . The duration study period 54 week total , comprise 2-week screening period 52-week treatment period .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Propiverine</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<criteria>Female : OAB outpatient postmenopausal least 1 year Male : OAB outpatient wish child future Patient treatment mirabegron stable dose 50 mg daily least 6 week start screen period Patient walk bathroom without assistance Patient total Overactive Bladder Symptom Score ( OABSS ) ≥3 point Question 3 score ≥2 point Patient establish diagnosis stress urinary incontinence ( patient symptom stress urinary incontinence ) Patient urinary tract infection ( cystitis , prostatitis , etc . ) , urinary calculus ( ureteric calculus , urethral calculus , bladder calculus , etc . ) , interstitial cystitis , history recurrent urinary tract infection ( least 3 episode within 24 week start screen period ) Patient residual urine volume ≥100 mL week 2 visit patient benign prostatic hyperplasia lower urinary tract obstruction Patient uncontrolled hypertension ( sit systolic blood pressure ≥180 mmHg diastolic blood pressure ≥110 mmHg week 2 visit ) Patient pulse rate ≥110 bpm &lt; 50 bpm week 2 visit Anticholinergics contraindicate ( urinary retention ; obstruction pylorus , duodenum , intestine ; paralytic ileus ; gastric/intestinal atony ; myasthenia gravis ; decrease gastrointestinal motility/tone , etc . ) patient . Patient glaucoma , ulcerative colitis , hyperthyroidism , dementia , cognitive dysfunction , parkinsonism symptom , clinically significant cerebrovascular disorder Patient serious heart disease ( myocardial infarction , cardiac failure , uncontrolled angina pectoris , serious arrhythmia , use pacemaker , etc . ) , liver disease , kidney disease , immunological disease , lung disease , etc . patient history malignant tumor ( except malignant tumor treat least 5 year start screen period risk recurrence ) Patient drug hypersensitivity βagonists anticholinergic Patient treatment flecainide acetate propafenone hydrochloride Patient long QT syndrome , patient vulnerable arrhythmia bradycardia acute myocardial ischemia , patient hypokalemia , patient ischemic heart disease angina pectoris Patient use prohibit concomitant medication within 4 week start screen period Patient catheterization intermittent selfcatheterization patient pelvic organ prolapse affect urinary tract function Patient receive radiotherapy affect urinary tract function Patient receive surgical therapy may affect urinary tract function within 24 week start screen period Patient receive nonpharmacological therapy OAB electric stimulation therapy ( interferential low frequency therapy , magnetic stimulation therapy , etc . ) , biofeedback therapy , bladder training , pelvic floor muscle exercise within 2 week start screen period Patient history mood disorder , neurotic disorder , schizophrenia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Anticholinergic</keyword>
	<keyword>Overactive Bladder ( OAB )</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>YM178</keyword>
</DOC>